UPDATE 1-Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Biohaven Pharmaceutical said on Friday it would continue its late-stage study of experimental treatment for the symptoms of Alzheimer's on the recommendation of an independent data-monitoring committee, sending its shares up 11.6%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.